EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Antigen loss following CAR‐T cell therapy: Mechanisms, implications, and potential solutions

Archana Mishra iD, Rituparna Maiti iD, Prafull Mohan iD, Pooja Gupta iD

European Journal of Haematology · 2024-02 · 112 (2) · 211-222

DOI: 10.1111/ejh.14101 ↗

At a glance

Übersichtsarbeit in European Journal of Haematology, published online on 2023-09-13. Written by Archana Mishra and 3 co-authors. Institution: Department of Pharmacology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India. Major MEDLINE topics: Receptors, Chimeric Antigen. Cited 68 times so far (Crossref); 80 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Chimeric Antigen Receptor T‐cell (CAR‐T cell) therapy has emerged as a groundbreaking immunotherapeutic approach for treating various hematological malignancies. CAR‐T cells are engineered to express synthetic receptors that target specific antigens on cancer cells, leading to their eradication. While the therapy has shown remarkable efficacy, a significant challenge that has been observed in 30%–70% of patients showing recurrent disease is antigen loss or downregulation. We searched PubMed/MEDLINE, EMBASE, and Google scholar for articles on antigen loss/escape following Chimeric antigen receptor T‐cell therapy in malignancies. Antigen loss refers to the loss or reduction in the expression of the target antigen on cancer cells, rendering CAR‐T cells ineffective. This phenomenon poses a significant clinical concern, as it can lead to disease relapse and limited treatment options. This review explores the mechanisms underlying antigen loss following CAR‐T cell therapy, its implications on treatment outcomes, and potential strategies to overcome the problem.

Subjects

MeSH terms (MEDLINE)

Receptors, Chimeric AntigenHumansReceptors, Antigen, T-CellT-LymphocytesNeoplasm Recurrence, LocalImmunotherapy, AdoptiveCell- and Tissue-Based Therapy

Author keywords

CAR-Tantigen lossdual targeted CARnovel CAR designs

Substances

Receptors, Chimeric AntigenReceptors, Antigen, T-Cell

Authors and institutions

  • Department of Pharmacology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
  • Clinical Pharmacologist, Armed Forces Medical Services, Guwahati, India.
  • Department of Pharmacology, All India Institute of Medical Sciences, Delhi, India.

ORCID profiles: Archana Mishra, Rituparna Maiti, Prafull Mohan, Pooja Gupta

Cite

APA

Mishra, A., Maiti, R., Mohan, P., & Gupta, P. (2024). Antigen loss following CAR‐T cell therapy: Mechanisms, implications, and potential solutions. European Journal of Haematology, 112(2), 211-222. https://doi.org/10.1111/ejh.14101

Vancouver

Mishra A, Maiti R, Mohan P, Gupta P. Antigen loss following CAR‐T cell therapy: Mechanisms, implications, and potential solutions. European Journal of Haematology. 2024;112(2):211-222. doi:10.1111/ejh.14101

BibTeX
@article{Mishra2024,
  author = {Mishra, Archana and Maiti, Rituparna and Mohan, Prafull and Gupta, Pooja},
  title = {Antigen loss following CAR‐T cell therapy: Mechanisms, implications, and potential solutions},
  journal = {European Journal of Haematology},
  year = {2024},
  volume = {112},
  number = {2},
  pages = {211--222},
  doi = {10.1111/ejh.14101}
}
Start for free →